Casgevy Approvals Expand to 10 Countries as CRISPR Enters Mainstream

The first CRISPR-based therapy, Casgevy for sickle cell disease and beta-thalassemia, is now approved in the US, EU, UK, Canada, and six additional countries. Real-world data confirms durable transfusion independence.